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ABSTRACT 
This study investigates the opioid effect of αs1-casein fragments related to 143AYFYPEL149 and 
144YFYPEL149, which had previously shown mucin-stimulatory activity in human goblet cells. 
Peptides 144YFYPEL149 and 144YFYPE148 showed opioid agonistic activity in guinea pig ileum, and 
in mouse vas deferens but to a lower extent. Peptides were partly hydrolysed during the assay 
and several of the resulting fragments lost the N-terminal Tyr residue. Docking of peptides 
144YFYPEL149 (active) and 144YFYP147 (inactive) into the active site of the opioid receptor model 
showed remarkable differences regarding the flexibility at the third intracellular loop of the 
receptor and the interaction with Pro at the peptide C-terminus that forced residues Arg148 and 
Glu166 from the receptor to move towards the interior of the binding pocket. The study on 
human cells HT29-MTX has shown that αs1-casein 144YFYPEL149 is the minimum fragment able to 
stimulate MUC5AC expression. 
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HIGHLIGHTS: 
144YFYPEL149 and 144YFYPE148 demonstrated opioid activity on guinea pig ileum 
144YFYPEL149 and 144YFYP147 presented different behaviour against opioid receptor 
144YFYPEL149 was the minimum fragment with stimulatory effect on MUC5AC expression 
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1. INTRODUCTION 
During food digestion, proteins render a large variety of different peptides. Some of 
these sequences are structurally similar to endogenous physiologically active peptides and 
therefore, these food-derived sequences can interact with the same receptors in the organism, 
exerting an agonist or antagonist activity. One of the best examples where this applies, are 
food-derived opioid peptides, i.e., exogenous opioid receptor ligands with agonistic activity. 
From milk, peptides derived from β-casein, referred as β-casomorphins, were the first food 
protein-derived opioid receptor ligands whose sequences were identified (Brantl, 
Teschemacher, Henschen, & Lottspeich, 1979). They have been found in in vivo digestion 
products from humans and minipigs (Barbé et al., 2014; Boutrou et al., 2013). The common 
structural characteristics of both, exogenous and endogenous opioid peptides, are the 
presence of a tyrosine residue at the N-terminus and the presence of other aromatic residue, 
phenylalanine or tyrosine, in the third or fourth position (Meisel, 1997). In case of the αs1-
casein derived peptides or α-casein exorphins, the active sequence can contain an additional 
arginine residue at the N-terminus. Although caseins are source of many peptides showing 
agonist or antagonist action on different opioid receptors, opioid peptides from other protein 
sources have been also described, such as whey proteins (Antila et al., 1991) and hemoglobin 
(Zhao, Garreau, Sannier, & Piot, 1997) from animal sources and gluten, rice, or soy from plant 
proteins (Yoshikawa, 2015). 
Biological activities observed for these food-derived opioid sequences include 
analgesia and modulation of social behaviour, after parenteral or intracerebral administration 
to animals. Orally administered food-derived opioid peptides have demonstrated to influence 
postprandial metabolism by stimulating secretion of insulin and somatostatin, prolongation of 
gastrointestinal transit time, stimulation of food intake, and effects on the immune system, 
among others (for reviews regarding biological activity, see Meisel & FitzGerald, 2000; 
Rutherfurd-Markwick, 2012; Teschemacher, 2003; Teschemacher, Koch & Brantl, 1997). 
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Moreover, it was found that the opioid peptide β-casomorphin-7 (60YPFPGPI66) induced 
intestinal mucin release through a nervous pathway and opioid receptor activation in ex-vivo 
preparations of rat jejunum (Claustre et al., 2002; Trompette et al., 2003). In human (HT29-
MTX) and rat (DHE) intestinal mucin-producing cells, this peptide increased secretion and 
expression of mucin, and these effects were prevented with the μ-opioid antagonist 
cyprodime (Zoghbi et al., 2006). Similar effects were reported for the μ-opioid ligands, α-
lactorphin (Martínez-Maqueda et al., 2012) and β-lactorphin (Martínez-Maqueda, Miralles, 
Ramos, & Recio, 2013b). However, other β-casein-derived peptides whose structures do not 
fulfil the requirements of opioid ligands have also demonstrated regulation of mucin 
production in HT29-MTX cells and in animals, such as the peptide β-CN f(94-123) found in 
yogurts and the derived fragments (94-108) and (117-123) (Plaisancié et al., 2013; Plaisancié et 
al., 2015). 
Our group had shown the mucin secretory activity of various bovine αs1-casein-derived 
peptides with favourable structures to bind opioid receptors due to the presence of Tyr at the 
N-terminus or in the second position and other Tyr in the third or fourth position. From these 
peptides, fragments 143AYFYPEL149, 144YFYPEL149 and a casein hydrolysate containing both 
sequences produced an increased mucin secretion and MUC5AC gene expression in HT29-MTX 
cells (Martínez-Maqueda, Miralles, Cruz-Huerta, Recio, 2013a). Interestingly, these two 
peptides had been identified in in vivo gastric and duodenal human digests after milk ingestion 
(Chabance et al., 1998). However, despite the favourable structure of these sequences and 
their potential to interact with opioid receptors located at the intestinal tract, the opioid 
activity of these peptides has not been previously demonstrated. The objective of this work 
was to investigate the opioid effect of the bovine αs1-casein fragment 143AYFYPEL149, and four 
derived peptides comprising the core structure for opioid activity YFY in guinea pig ileum and 
mouse vas deferens preparations. A molecular docking of two peptides into the active site of 
the μ-opioid receptor was carried out to identify the key residues responsible for the affinity to 
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the receptor. In addition, a preliminary study of these sequences on MUC5AC gene 
overexpression in HT29-MTX cells is shown. 
 
2. MATERIALS AND METHODS 
2.1. Peptides  
αs1-casein fragments 143AYFYPEL149, 144YFYPEL149, 144YFYPE148, 144YFYP147 and 144YFY146 , 
and the β-casein fragment 60YPFPGPI66 were synthesized in house using conventional solid-
phase FMOC synthesis with a 433A peptide synthesizer (Applied Biosystems, Warrington, UK). 
In the peptide purification protocol, the treatment with acetic acid was included to replace 
trifluoroacetic acid which affects the pH of the peptide solutions in the bioassays. Their purity 
(>90%) was verified in our laboratory by reverse phase high performance liquid 
chromatography and tandem mass spectrometry (HPLC-MS/MS). 
 
2.2. Isolated preparations from guinea pig ileum and mouse vas deferens 
Female guinea-pigs weighing 300-450 g, and male CD-1 mice weighing 25-60 g were 
used. Myenteric plexus-longitudinal muscle strips (MP-LM) from guinea pig ileum, and the 
mouse vas deferens were isolated as described by Ambache (1954) and Hughes et al. (1975), 
respectively. Tissues were suspended in a 10 ml organ bath containing 5 ml of Krebs solution 
(NaCl 118, KCl 4.75, CaCl2 2.54, KH2PO4 1.19; MgSO4 1.2; NaHCO3 25; glucose 11mM). This 
solution was continuously gassed with 95% O2 and 5% CO2. Tissues were kept under 1 g 
(guinea pig ileum) or 0.5 g (mouse vas deferens) of resting tension, at 37 ºC and were 
electrically stimulated through two platinum ring electrodes. MP-LM strips were stimulated 
with rectangular pulses of 70 V, 0.1 ms duration and 0.3 Hz frequency, and mouse vas deferens 
with trains of 15 rectangular pulses of 70 V, 15 Hz and 2 ms duration each min. The isometric 
force was monitored by computer using a MacLab data recording and analysis system. In both 
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assays the interval between applications of increasing concentrations was optimized to obtain 
a stable signal, and it was 9 min for αs1-casein peptides, and 3 min when control opioid 
agonists were tested. To evaluate the opioid-agonistic activity of peptides in the guinea pig 
ileum, cumulative concentration-response curves with five doses in the range 6.1 × 10-8 – 1.0 × 
10-5 M were constructed in a step by step manner as follows: after 15 min-stabilisation of MP-
LM strips in organ bath, electrical stimulation was applied, and peptide´s effect on the 
electrically induced contractions was evaluated once the response reached a plateau. 
Morphine was used as µ-opioid agonist positive control. To corroborate that the inhibitory 
effect of the peptides was mediated through interaction with opioid receptors, one dose of 
naloxone (1.0 × 10-6 M, Sigma), an non-selective opioid antagonist, was added to the organ 
bath at the end of each experiment. In mouse vas deferens preparations, non-cumulative 
concentration-response curves with four doses in the range 5.5 × 10-7 – 1.0 × 10-5 M were 
tested. Once tissue stabilisation, the first peptide dose was added and evaluated. The tissue 
was then washed, and subsequent doses were applied. In this preparation, [D-Pen(2),D-
Pen(5)]-enkephalin (DPDPE) was used as δ-opioid agonist, and one dose of naltrindole (1.0 × 
10-9 - 1.0 × 10-7  M, Sigma), a δ-selective opioid antagonist, was added after the experiments to 
evaluate selective interaction with δ-opioid receptors. Results were expressed as % of 
inhibition, taking the mean amplitude of the last five contractions before the addition of the 
peptides as 100%. In guinea pig ileum, when the effect of peptidase inhibitors (captopril, 
amastatin and phosphoramidon 1.0 × 10-6 M, Sigma) was evaluated, they were added 5 min 
before the beginning of the peptide´s concentration-response curve (Akahori et al., 2008). 
Each tissue was employed only once, with at least six biological replicates per condition. 
Experimental protocols used in this investigation were approved by the Ethical Committee of 
Rey Juan Carlos University. Data were analyzed using GraphPad Prism 5.03 software by a one-
way ANOVA, followed by the Bonferroni Multiple Comparison test. Differences between each 
dose with a P value < 0.05 were considered significant.  
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2.3. Analysis by HPLC-MS/MS 
In order to evaluate the stability of the peptides during the activity assay on MP-LM 
preparations, they were added at 5.0 × 10-6 M to the organ bath solution, and aliquots were 
withdrawn at time 0, 4, and 9 min, frozen immediately and kept at − 20 ºC until analysis. 
Analysis of the peptides was performed using an Acquity liquid chromatography system 
(Waters) connected to microToF II Quadrupole-Time-of-Flight mass spectrometer (Bruker). A 
Waters Acquity UPLC BEH C18 column 100 mm length, 2.1 mm internal diameter, 1.7 μm 
packing was used. A binary elution gradient, based on water (solvent A) and acetonitrile 
(solvent B), both containing 0.1% formic acid (v/v), and operated at a flow rate of 0.2 mL/min, 
was adopted. A gradient elution program based on solvent B increase from 0% to 70% in 30 
min was used. Column reconditioning at the initial mobile phase composition was 
accomplished in 15 min. ESI-MS acquisitions were carried out in positive ion mode. The LC-MS 
system was controlled by the HyStar 3.2 software (Bruker). The main parameters of the ESI 
interface and of the quadrupole were: Dry temperature 180 ºC; Dry gas flow 4.0 L/min; 
Nebulizer gas pressure 0.4 bar; Capillary voltage 4.5 kV; Quadrupole Ion Energy 5.0 eV. The ToF 
analyzer was calibrated on a daily basis in MS mode, using the m/z ratios of adduct ions arising 
from sodium formate as reference. 
2.4. Molecular modelling receptor-peptide 
Homology model of the µ-opioid receptor (UniProtKB - P35372 (OPRM_HUMAN)) was 
built by standard homology modeling techniques using MODELER version 9.7. (Eswar et al., 
2006), as described in the Supplementary Data. The structure of the human δ- and µ-opioid 
receptors (Protein Data Bank entries 4RWA and 5C1M) (Fenalti et al., 2015; Huang et al., 2015) 
were used as template. The structure of the bifunctional δ-opioid antagonist and µ-opioid 
agonist tetrapeptide Dmt-Tic-Phe-Phe-NH2 (Protein Data Bank entry 4RWA) was used as 
8 
 
template for docking the peptides 144YFYPEL149 and 144YFYP147 into the active site of the opioid 
receptor model. 
2.5. Cell culture 
HT29-MTX, a human colon adenocarcinoma-derived mucin-secreting goblet cell line 
was provided by Dr. Thécla Lesuffleur (Lesuffleur et al., 1993). The cell line was grown in plastic 
75-cm2 culture flasks in Dulbecco´s Modified Eagle´s medium supplemented with 10% fetal 
bovine serum and 10 mL/L penicillin-streptomycin solution (all from Gibco, Paisley, UK) at 37 
ºC in a 5% CO2 atmosphere in a humidified incubator. Cells were passaged weekly using 
trypsin/EDTA 0.05% (Gibco). The culture medium was changed every two days. To study the 
effect of peptides, cells were seeded at a density of 5 × 105 cells per well in 12-well culture 
plates (Nunc, Roskilde, Denmark). The cell line was used between passages 12 and 19. 
Experiments were performed 21 days after confluence. The culture medium was replaced, 24 
h before the studies, by serum- and antibiotic-free medium to starve the cells and to eliminate 
any interference from extraneous proteins or hormones. After serum-free medium removal, 
the monolayer was washed twice with PBS. Serum-free medium with or without peptide (5.0 × 
10-5, 1.0 × 10-4, and 5.0 × 10-4 M) was added to the cells and incubated at 37 ºC for 2 to 24 h in 
a 5% CO2 humidified atmosphere. The supernatants were collected, frozen and stored at -80 
ºC. The total RNA was isolated with Nucleospin® RNA II (Macherey-Nagel, Düren, Germany) 
according to manufacturer´s instruction. 
2.6. Quantitative RT-PCR assays (qRT-PCR) 
qRT-PCR amplification was carried out using a Lightcycler 480 (Roche, Mannheim, 
Germany) in 384 wells microplates (Roche). RNA (375 ng) was reverse transcribed using a High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to the manufacturer´s 
instruction. For MUC5AC (accession no. AJ001402), target gene, primers 2870-2889/3109-3091 
were used. For reference genes human cyclophilin (accession no. Y00052) and human β-actin 
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(accession no. NM_001101) primers 280-304/445-421 and 879-896/1076-1053, respectively, 
were used (Tai et al., 2008; Zoghbi et al., 2006). The SYBR Green method was used and each 
assay was performed with cDNA samples in triplicate. Each reaction tube contained 5 μL 2x 
SYBR Green real-time PCR Master Mix (Roche), 0.25 μL of a 10 μM of gene-specific forward 
and reverse primers, 0.27 μL of cDNA (5.06 ng), and 4.23 μL of water. Amplification was 
initiated at 95 ºC for 5 min, followed by 45 cycles of 95 ºC for 10 s, 60 ºC for 10 s and 72 ºC for 
10 s. Control PCRs were included to confirm the absence of primer dimer formation (no-
template control), and to verify that there was no DNA contamination (without RT enzyme). All 
real-time PCR assays amplified a single product as determined by melting curve analysis. 
Amplification efficiencies of the target and reference genes were performed, and the relative 
expression levels of the target gene were calculated according to the 2-ΔΔCt method (Livak & 
Schmittgen, 2001). Human cyclophilin and human β-actin were tested as reference gene. 
Human cyclophilin gene was then chosen to calculate the threshold cycles because it had 
previously been shown to be constant under all conditions used. All experiments were 
performed at least three times in triplicate. Data were analyzed using GraphPad Prism 5.03 
software by a two-way ANOVA. For a better comparison of the concentration versus control 
data for each time, data were analyzed by one-way ANOVA, followed by the Newman-Keuls 
test. Differences between means and controls with a P value < 0.05 (*), or P value < 0.01 (**) 
were considered significant. 
 
3. RESULTS 
3.1. Activity of αs1-casein fragment 143AYFYPEL149 and derived peptides on guinea pig ileum 
and mouse vas deferens preparations 
As illustrated in Figure 1, the inhibition of the electrically induced contractions in MP-
LM preparations in cumulative curves of five doses showed a significative increase upon 
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addition of the αs1-casein peptides 144YFYPEL149, and 144YFYPE148 between the first and the third 
dose but the curve did not show any further increase. The other peptides, 143AYFYPEL149, 
144YFYP147 and 144YFY146, did not show inhibitory effect on this preparation. The maximum 
inhibition responses for 144YFYPEL149 (35.1 ± 5.6%), and 144YFYPE148 (31.8 ± 2.5%), were reached 
at a dose 5.5 × 10-7 M and it was followed by a smooth decrease. As positive controls, β-
casomorphin-7 (YPFPGPI) and morphine were used. β-casomorphin-7 showed an increasing 
trend up to 1.0 × 10-5 M with a maximum response of 23.3 ± 5.1%, while the morphine 
inhibition curve increased up to 1.6 × 10-6 M reaching a 60.6 ± 5.8% of inhibition on the 
electrically stimulated contractions of the MP-LM preparations. In this latter case, the plateau 
observed for the highest concentration (5.0 × 10-6 M) could be due to receptor saturation. 
However, the decreasing trend of the curves obtained for the αs1-casein-derived peptides from 
the third dose led us to consider the possibility of peptide degradation in the organ bath. In 
order to check peptide stability during the experiments, aliquots of the organ bath were 
withdrawn at time 0, 4 and 9 min and analysed by HPLC-MS/MS. The chromatographic areas of 
the extracted molecular ion corresponding to the assayed peptides showed a decrease with 
the time (Supplementary Figure 1). The observed decrease in the area of intact peptide was 
accompanied with the increase of derived peptide fragments, which could be also identified by 
their fragmentation pattern. In this way, from peptide 143AYFYPEL149 increasing concentrations 
of fragments 144YFYPEL149, 145FYPEL149, and 146YPEL149 were detected over time; from peptide 
144YFYPEL149, fragments 145FYPEL149, 146YPEL149, and 144YFYP147 were found; and from 144YFYPE148, 
the formation of 145FYPE148 could be followed. No peptide fragments were detected for 
144YFYP147 or 144YFY146, although a concentration decrease ca. 34% and 29% was found from 0 
to 9 min, respectively. For these two short peptides, it is possible that although peptide 
degradation could occur, the derived peptide fragments could not be detected due the short 
size of the fragments. It has to be noted that some of the new peptide fragments generated by 
the action of tissue peptidases preserved the cluster 144YFY146, but in other cases the N-
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terminal Tyr residue was lost, and therefore, presumably their potential opioid effect. Since 
the lost in opioid effect along the accumulative dose-response curve could be attributed to the 
peptide degradation over time, the assays were repeated in the presence of three peptidase 
inhibitors.  
Figure 2 shows the inhibition curves for peptides 143AYFYPEL149, 144YFYPEL149, 
144YFYPE148, 144YFYP147 and 144YFY146 when peptidase inhibitors captopril, amastatin and 
phosphoramidon were used. The inhibition curves for all peptides, except 144YFYP147, showed 
an increasing trend with the peptide concentration and a significant dose-effect was found for 
various peptides, such as, 144YFYPEL149 and 144YFY146. Peptide 144YFYPE148 reached the highest 
mean inhibitory value, 31.6 ± 4.6%, although the inhibition percentages determined for 
143AYFYPEL149, 144YFYPEL149, and 144YFY146 were not significantly different to this, being 22.2 ± 
4.1, 26.2 ± 4.9 and 25.5 ± 5.3%, respectively. The suppressive effect of these peptides on the 
electrically stimulated contractions in MP-LM preparations was reverted by the use of 
naloxone at 1.0 × 10-6 M, once the maximum concentration of the peptide was tested. In 
addition, the stability of the peptides over the time in the presence of peptidase inhibitors was 
also evaluated, as previously. As expected, derived peptide fragments were not detected or 
their intensities were considerably lower (data not shown). 
In the mouse vas deferens preparation, αs1-casein-derived peptides showed lower 
activity. Peptides 143AYFYPEL149, 144YFYPEL149 and 144YFYPE148 induced a maximum inhibitory 
effect of the contractions of 8.8 ± 3.4, 6.9 ± 1.6 and 13.4 ± 2.8%, respectively, at the highest 
dose assayed (1.0 × 10-5 M), with a dose-effect trend only found for 144YFYPE148. The positive 
control, DPDPE, also showed a dose-dependent activity, with the maximum inhibitory effect 
found at 6 × 10-8 M (55.3 ± 10.2 %). By the addition of naltrindole (1 × 10-9 M), a selective δ-
opioid receptor antagonist, DPDPE effect was partly reversed (36.0 ± 7.9 %), while the weak 
activity found for the peptides was not affected. 
12 
 
3.2. Molecular modelling of the µ-opioid receptor bound to αs1-casein peptides 
 To better understand the opioid activity of these αs1-casein peptides and aiming to 
elucidate a structure-activity relationship, molecular dynamics simulations of peptides binding 
at µ-opioid receptor were performed. As representative examples, peptides 144YFYPEL149 and 
144YFYP147 were chosen for these experiments to explain the lack of activity of the shorter form, 
according to results on guinea-pig ileum preparations.  
The structural stability of the complex receptor-peptide was evaluated by monitoring 
the Root-Mean-Square Deviation (RMSD) between different structures sampled along the 
simulation. The fluctuations of the individual residues from the receptor and the peptides 
were studied. In both cases, intra and extra loops of the receptor exhibited the greatest 
variability, most noteworthy loops between residues 145-150, 195-200, 240-250 and the C-
terminal domain of the receptor (Figure 3A). However, when peptide 144YFYP147 was assayed 
the loop between residues 195-200 started the simulation with a retracted loop but it became 
stretched maintaining this position for the rest of the simulation (Figure 3B). While peptide 
144YFYPEL149 stays stable at the active site at its first three residues and fluctuates due to the 
repositioning of its last two residues, movements of peptide 144YFYP147 are mainly due to 
residues Tyr at the third position and Pro at the C-terminus, as consequence of the new C-
terminal group. 
As shown in Table 1 and supplementary Figure 2 the interaction energy of the different 
amino acid residues of the peptides at the active site of µ-receptor was calculated. The 
position of peptide 144YFYPEL149 at the base of active site is stabilized by strong van der Waals, 
hydrogen bond, and charge-charge interactions. This is clearly seen at the final model where 
the interactions of the residues of the receptor Asp84, Tyr263, His234, and Trp230 interact with Tyr 
at the peptide N-terminus stabilizing this position (Figure 4A). Peptide Phe and Tyr residues, at 
the second and third position, respectively, showed strong hydrogen bonds and van der Waals 
13 
 
interactions between their aromatic rings and compatible µ-receptor residues that also help N-
terminal Tyr to maintain its right configuration (Figure 4B and 4C). At the top of the cavity, 
peptide Glu and Leu establish charge-charge and hydrogen bonds interactions, building a 
network of electrostatic interactions between the peptide, some water molecules, and the last 
residues of the cavity (Figure 4D). In the case of peptide 144YFYP147, the behaviour of the N-
terminal Tyr at the right side of the binding pocket resembles that described above for 
144YFYPEL149 (Figure 4E). However the interaction between the Tyr at the third position and the 
Gln61 residue from the receptor changes from van der Waals-type to hydrogen bond-type 
(Table 1). Moreover, an additional hydrogen bond is established with Tyr85, instead of Tyr12 as 
before. Consequently, as shown in Figure 4G, the orientation of the second Tyr residue from 
144YFYP147 differs from that of peptide 144YFYPEL149. In addition, the C-terminal Pro residue from 
144YFYP147 played a remarkable role in receptor-peptide relation, not described in the case of 
144YFYPEL149, by establishing a strong charge-charge-type interaction with Arg148, which 
modifies the configuration of this location (Table 1 and Figure 4H). 
The interactions of peptide-receptor residues were monitored during the simulation 
time (45 ns). In case of peptide 144YFYPEL149, interactions with N-terminal Tyr were stable 
during the simulation, whereas for the rest of residues interactions became stronger as the 
simulation progressed (Supplementary Figure 3). However, main interactions of peptide 
144YFYP147 seem to follow a different behaviour. Whereas Tyr at the peptide N-terminus and 
Asp84 maintained a quite stable interaction, this peptide residue lost interaction strength with 
Tyr85 after 10 ns, and with Tyr263 and His234 at the last steps of the simulation. It is remarkable 
that the second peptide Tyr residue began to show a tough interaction with Tyr85, Asp84, and 
Ile81 at the opioid receptor after 20 ns. Similarly, C-terminal Pro increased interaction with 
Arg148 and Thr155 at the end of the simulation. All these modifications might be most likely due 
to a change in the peptide-receptor orientation. 
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3.3. Activity of bovine αs1-casein-derived peptides 144YFYPE148, 144YFYP147 and 144YFY146 on 
MUC5AC expression 
Because peptides 143AYFYPEL149 and 144YFYPEL149 had previously demonstrated 
stimulatory effect on mucin secretion and MUC5AC gene expression (Martínez-Maqueda et al., 
2013a), the effect of the shorter derived peptides on HT29-MTX cells was also evaluated. The 
relative expression of MUC5AC was determined by qRT-PCR after exposure of HT29-MTX cells 
to the peptides. Table 2 shows the maximum relative MUC5AC expression level along 24 h of 
treatment with 144YFYPE148, 144YFYP147, and 144YFY146 at three concentrations (5.0 × 10-5, 1.0 × 
10-4, and 5.0 × 10-4 M). Although treatment with 144YFY146 showed increased levels of MUC5AC 
after 24h at the three concentrations, these values did not reach significance due to the high 
variability between replicates. For the other two peptides 144YFYPE148, 144YFYP147, no significant 
MUC5AC over-expression was observed compared with controls (untreated cells). From these 
two latter peptides, only 144YFYPE148, but not 144YFYP147, had demonstrated the ability to inhibit 
electrically stimulated contractions in MP-LM. According to these results, the assayed shorter 
forms exhibited different behaviour on the mucin gene expression in HT29-MTX cells than the 
longer peptides 143AYFYPEL149 and 144YFYPEL149. 
 
4. DISCUSSION 
β-casomorphins were the first food-derived opioid peptides and were found in a casein 
hydrolysate in 1979 (Brantl et al., 1979). Since then, different opioid peptides derived from 
milk proteins and other food proteins have been described. The present study was undertaken 
to examine if two αs1-casein-derived sequences, 143AYFYPEL149 and 144YFYPEL149, which share 
some structural characteristics with previously described opioid peptides, could also exert this 
effect. These two sequences, found in a peptic casein hydrolysate, had also demonstrated to 
stimulate mucin secretion and gene expression in HT29-MTX cells (Martínez-Maqueda et al., 
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2013a), and it had been suggested that this effect could be mediated by interaction with μ-
opioid receptors (Zoghbi et al., 2006). The results of this study showed, for the first time, 
opioid activity in the guinea pig MP-LM preparation for various related αs1-casein sequences, 
especially 144YFYPEL149 and 144YFYPE148. Other related fragments, 143AYFYPEL149 and 144YFY146 
were able to exert this effect, but only when peptidase inhibitors were added to the 
preparation. 
In view of their structures, opioid peptides have been divided into two groups designated 
as “typical” and “atypical” (Teschemacher et al., 1997). “Typical” opioid peptides exhibit the 
definite N-terminal sequence YGGF, characteristic of the endogenous opioid peptides: 
enkephalins, endorphins, and dynorphins. “Atypical” peptides are characterized by the 
presence of Tyr at the N-terminus which is a structural motif important in ligand-receptor 
binding, although this N-terminal residue is not present in nociception/orphanin FQ 
(Reinscheid et al., 1995). The αs1-casein derived peptides studied in this work share some 
structural characteristics with previously described αs1-casein exorphins. Loukas, Varoucha, 
Zioudrou, Streaty, and Klee (1983) identified various αs1-casein opioid peptides, 90RYLGYLE96, 
90RYLGYL95 and 91YLGYLE96 from a digest of casein with pepsin. Similarly to αs1-casein exorphins, 
peptides in this work were identified in a peptic casein hydrolysate and also possess two Tyr 
residues, in our case separated by a Phe residue instead by the dipeptide LG, as occurs in the 
peptides previously described. In addition, some αs1-casein exorphins are characterized by the 
presence of an additional Arg residue at the N-terminus. Our results show by comparison of 
the activity of 143AYFYPEL149 and 144YFYPEL149 that the presence of an additional Ala residue at 
the N-terminus diminishes the effect on the guinea pig ileum preparation, when no peptidases 
inhibitors were used. However, in presence of peptidases inhibitors 143AYFYPEL149 exerted 
certain activity, and therefore, the lack of activity in absence of peptidase inhibitors might be 
explained by a rapid peptide degradation. 
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Peptides in this study, especially 144YFYPEL149 and 144YFYPE148, showed naloxone-
antagonizable inhibitory effect in the electrically stimulated guinea pig ileum preparation. This 
isolated tissue possesses both, μ- and κ-opioid receptors that regulate the contractile response 
when stimulated by inhibiting acetylcholine release during electrical stimulation of the 
myenteric plexus neurons. Although this preparation also contains cannabinoid, adenosine and 
adrenergic receptors (Taylor, 2011), the reversion of the effect by naloxone, a competitive 
antagonist at μ, δ, and κ-opioid receptors, proved the participation of these receptors on the 
effect of the assayed peptides. However, lower effects were found in the mouse vas deferens. 
This tissue can be used to study all three opioid receptor subtypes, but the expression of μ- 
and κ-opioid receptors is lower in this preparation than in guinea pig ileum (Taylor, 2011), 
being the δ-opioid the predominant receptor subtype (Lord, Waterfield, Hughes, & Kosterlitz, 
1977). The activity of the assayed peptides in mouse vas deferens was not reverted by the use 
of naltrindole which suggests poor affinity for δ-opioid receptors. Likewise, bovine β-
casomorphins have been also demonstrated to exert a higher opioid activity in the guinea pig 
ileum than in the mouse vas deferens assay (Brantl, Teschemacher, Bläsig, Henschen, & 
Lottspeich, 1981). On the contrary, the previously described αs1-casein exorphins 
demonstrated a moderated effect on inhibition of adenyl cyclase in neuroblastoma × glioma 
hybrid cells, as well as, inhibition of contractions in mouse vas deferens, suggesting selectivity 
for δ-opioid receptors (Loukas et al., 1983). The assayed peptides show structural homologies 
with β-casomorphins, with an aromatic residue at the first and third position and a proline 
residue at the fourth position from the N-terminal. This is in agreement with the higher activity 
found in the guinea pig ileum preparation. Therefore, further studies with selective opioid 
antagonists such as β-funaltrexamine, naltrindole, and nor-binaltorphimine for μ-, δ-, and κ-
opioid receptors, respectively, are required to evaluate the selectivity of the active peptides 
found in this study on different receptor subtypes. 
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Regarding activity, these peptides containing the tripeptide YFY were found to exert an 
agonist opioid effect on guinea pig ileum preparations, although moderate in strength. 
However, it has to be pointed that under our experimental conditions, i.e., application of 
increasing concentrations at 9 min intervals, peptide β-casomorphin-7, which was used as 
positive control, did not reach the activity values previously reported in guinea pig ileum 
preparations, with IC50 values between 3.2 × 10-6 and 6.9 × 10-6 M (Jinsmaa & Yoshikawa, 1999; 
Koch, Wiedemann, & Teschemacher, 1985; Yoshikawa, Fumito, Takashi, & Hideo, 1986). The 
time intervals used in this study were optimized to ensure signal stability. In addition, the 
stability of the assayed peptides in the organ bath was studied by HPLC-tandem mass 
spectrometry. It was demonstrated that these peptides were partly hydrolysed by the action 
of ileum peptidases within 9 min and some of the generated fragments lost the N-terminal Tyr 
residue characteristic of opioid peptides. In fact, it has been reported that endogenous opioid 
peptides, with homologous structure than the assayed peptides, are particularly sensitive to 
rapid hydrolysis by a number of peptidases that are present in the guinea pig ileum, as well as 
in other tissues (McKnight, Corbett, & Kosterlitz, 1983). From our results, it was also shown 
that the shape of the inhibition curve changed by the use of the three peptidase inhibitors but 
the maximum inhibitory activity did not significantly increase (Figure 1 vs. Figure 2). The 
change in the accumulative inhibition curves, compared to experiments conducted in absence 
of peptidase inhibitors confirmed that the decrease observed at higher doses in the absence of 
peptide inhibitors is caused by the peptide degradation during the assay. The combination of 
these peptidase inhibitors (captopril, amastatin and phosphoramidon 1.0 × 10-6 M) was not 
able to change the activity of morphine, DAMGO and metabolically stable synthetic opioid 
peptides in this preparation (Hiranuma et al., 1998). Aoki, Kajiwara, and Oka (1984) and 
McKnigh et al. (1983) demonstrated that the peptidase inhibitors mixtures captopril 1.0 × 10-6, 
bestatin 10.0 × 10-6, and thiorphan 1.0 × 10-6 M; and captopril 10.0 × 10-6, bestatin 10.0 × 10-6, 
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thiorphan 0.3 × 10-6, and L-Leu-L-Leu 2.0 × 10-3 M, respectively, did not affect, alone nor in 
combination, the contraction of the guinea pig MP-LM. 
In order to explain the different opioid activity found for these structurally similar 
peptides, molecular dynamic simulations were performed with 144YFYPEL149 which showed 
opioid activity in guinea pig ileum and 144YFYP147 which was inactive. The homology model of µ-
opioid receptor with the peptides docked at the active site was evaluated by the study of the 
energy stability and the identification of those responsible binding-residues at the cavity. The 
simulations with both peptides showed a notably energy variability in intra- and extra-cellular 
loops of the receptor at positions 145-150, 195-200, 240-250 and the C-terminal domain. This 
structural flexibility is in agreement with previous studies with the μ-opioid receptor (Serohijos 
et al., 2011). Similarly, it has been found that morphine leads to a greater flexibility of the third 
intra-cellular loop of the receptor, which is consistent with the critical role of this loop as the 
docking site of G-proteins binding (Waldhoer, Bartlett, & Whistler, 2004). Due to the flexibility 
observed in our simulation, it can be suggested that peptide 144YFYPEL149 behaves as an opioid 
agonist. For peptide 144YFYP147, the flexible areas of the receptor were similar, but a 
remarkable difference was found at the movement of the loop 195-200, which is related to the 
activity of the receptor. In addition, while peptide 144YFYPEL149 evoked a continuous change in 
this loop during the simulation, with peptide 144YFYP147 it became fixed. Moreover, it has been 
found that both peptides establish two strong hydrogen bonds and a charge-charge 
interaction, in the same way as the morphinan agonist BU72 (Huang et al., 2015), between the 
N-terminal Tyr at the peptide and Tyr263, His234, and Asp84 residues. However, and in contrast 
with the 144YFYPEL149 simulation, the second Tyr residue and Pro from 144YFYP147 were found to 
create different interactions with the receptor, resulting in a clear change between the 
locations of both peptides at the active binding site. Besides, another fact that might 
contribute to the different behaviour is the orientation of Arg148 and Glu166 receptor residues. 
When peptide 144YFYP147 was bound to the receptor, Arg148 and Glu166 residues had to move 
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towards the interior of the binding pocket to interact with C-terminal Pro of 144YFYP147. This 
process would require a large amount of energy due to their charged character, and when 
exposed to the solvent, would be highly solvated. The energy needed to remove this solvation 
shell might render peptide 144YFYP147 inactive. 
Previously, Zoghbi et al. (2006) had reported the activity of β-casomorphin-7 on mucin 
production in HT29-MTX cells via µ-opioid interactions. Given the effect observed in guinea pig 
ileum preparations, it was expected that in addition to 143AYFYPEL149 and 144YFYPEL149, peptide 
144YFYPE148 could also induce MUC5AC gene expression. However, although this peptide at 1.0 
× 10-4, and 5.0 × 10-4 M showed increased expression levels over the control, it did not reach 
significance. There is sufficient literature that illustrates the lack of correlation between μ-
opioid potency and effect on mucin secretion or gene overexpression. For instance, in a 
screening of several peptides with proved or probable μ- and δ-opioid activity, six out of eight 
peptides induced mucin secretion in HT29-MTX cells (Martínez-Maqueda et al., 2012). The 
evaluation of the effect on MUC5AC expression by α-lactorphin-amide and human β-
casomorphin-5 revealed that only the first provoked a significant gene overexpression, despite 
both had behaved as mucin secretors (Martínez-Maqueda et al., 2012), being β-casomorphin-5 
more potent than α-lactorphin-amide in guinea pig preparations (IC50 values of 14 × 10-6, and 
50 × 10-6 M, respectively) (Yoshikawa et al., 1986). Similarly, a recent report has shown that 
the μ-opioid peptide neocasomorphin-6 (YPVEPF) induced a significant rise in the 
transmembrane-associated mucin gene MUC4 but without effect on neither the expression of 
secreted MUC2 and MUC5AC nor the release of mucin-like glycoprotein (Plaisancié et al., 
2015). The effect on mucin production by food protein hydrolysates and peptides appears to 
be mediated by more than one type of mechanism. It remains to be clarified in any of these 
αs1-casein peptide fragments might stimulate mucin secretion and/or induce mucin gene 
overexpression other than MUC5AC. 
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In conclusion, various αs1-casein fragments containing the tripeptide YFY, especially, 
144YFYPEL149, 144YFYPE148 have shown for the first time opioid activity in guinea pig ileum 
preparations. Other related fragments, 143AYFYPEL149 and 144YFY146 were able to exert this 
effect, but only when peptidase inhibitors were added to the preparation. This effect was 
antagonized by naloxone, which demonstrates the implication of opioid receptors. The 
susceptibility of these peptides to be hydrolysed by peptidases found in this tissue was 
demonstrated by HPLC-tandem mass spectrometry. Several of the resulting fragments lost the 
N-terminal Tyr residue, and therefore, the potential ability to interact with opioid receptors. 
Similarly to β-casomorphins, the assayed peptides exerted opioid activity on mouse vas 
deferens to a lower extent than in guinea pig ileum. The lack of activity of peptide 144YFYP147 
can be explained by the different position of the third intracellular loop at the receptor. In 
addition, it was found that interactions of Pro residue at 144YFYPEL149 and 144YFYP147 were 
established at different places of the receptor active site. The study of the MUC5AC expression 
in human goblet cells HT29-MTX has shown that bovine αs1-casein 144YFYPEL149 is the minimum 
fragment able to stimulate mucin production, whereas the smaller fragments 144YFYPE148, 
144YFYP147 and 144YFY146 had no effect on MUC5AC expression, although it cannot be discarded 
activity on other mucin mRNA levels or on mucin secretion. 
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FIGURE CAPTIONS 
Figure 1. Inhibition of the electrically induced contractions in guinea pig ileum preparations at 
increasing concentrations (cumulative curve) of αs1-casein fragment 143AYFYPEL149 (A), αs1-
casein fragment 144YFYPEL149 (B), αs1-casein fragment 144YFYPE148 (C), αs1-casein fragment 
144YFYP147 (D), αs1-casein fragment 144YFY146 (E), β-casein fragment (β-casomorphin-7, 
60YPFPGPI66) (F), and morphine (G). For clarity, food-derived peptides and morphine results are 
represented in the Y-axis up to 40 and 80% inhibition, respectively. Each point represents the 
mean % ± SEM (n = 6). Different letters denote statistically significant differences between 
concentrations (P < 0.05). 
Figure 2. Inhibition of the electrically induced contractions in guinea pig ileum preparations in 
presence of the peptidase inhibitors (captopril, amastatin, and phosphoramidon) at increasing 
concentrations (cumulative curve) of αs1-casein fragment 143AYFYPEL149 (A), αs1-casein fragment 
144YFYPEL149 (B), αs1-casein fragment 144YFYPE148 (C), αs1-casein fragment 144YFYP147 (D), and αs1-
casein fragment 144YFY146 (E). Each point represents the mean % ± SEM (n = 6). Different letters 
denote statistically significant differences between concentrations (P < 0.05). 
Figure 3. Mean residue fluctuations of the μ-opioid receptor and the αs1-casein fragment 
144YFYPEL149 (A) and the αs1-casein fragment 144YFYP147 (B). Structures of opioid receptor and 
peptides are represented as ribbons where the most moving regions are thicker and coloured 
in red-orange, while static regions are thinner and colored in blue. Third loop between 
receptor residues 195-200 is marked with an arrow. 
Figure 4. Final molecular dynamics structure of peptides 144YFYPEL149 (A-D) and 144YFYP147 (E-H) 
bound the μ-opioid receptor. Main residues involved in the interaction (showed as sticks) are 
highlighted in blue in the protein receptor, and those from the peptides in green. Interactions 
are shown by amino acid residue of each peptide 144YFYPEL149 and 144YFYP147, respectively: N-
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terminal Tyr (A and E); Phe (B and F); Tyr at third position (C and G); Pro-Glu-Leu from 
144YFYPEL149 (D) and C-terminal Pro from 144YFYP147 (H). 
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